Using of aspirin in the prevention of preeclampsia

Using of low dose aspirin in the prevention of preeclampsia in pregnant women with abnormal uterin Doppler at 11-14 weeks gestation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013072914198N1

Enrollment

100

Registered

2013-09-14

Start date

2013-06-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Preeclampsia. Condition 2: preeclampsia. Gestational [pregnancy-induced] hypertension with significant proteinuria ??? ???????? ????-??? ???????? ????-??? ???????? ?? ????? ??? ???????

Interventions

Intervention 1: Intrvention description:Tab ASA 80 mg daily after lunch. Intervention 2: Controlled trial:No treatment.

Treatment - Drugs

Intrvention description:Tab ASA 80 mg daily after lunch

Controlled trial:No treatment

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria:Singleton pregnancies at 11-14 weeks and with riskfactors for preeclampsia such as;nulliparous women. Exclusion criteria;Fetal chromosomal or structural abnormalities,allergy to acetylsalicylic tablets,medical conditions:renal,lupus and coronary artery heart disease,bleeding disorders.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Diagnosis of preeclampsia. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: Monitor of blood pressure and proteinuria.;Time of onset of preeclampsia. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: LMP and ultrasound at time of booking.;Criteria of severity of preeclampsia. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: Monitor for blood pressure and proteinuria and symptoms and signs.	—

Measure

Time frame

Diagnosis of preeclampsia. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: Monitor of blood pressure and proteinuria.;Time of onset of preeclampsia. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: LMP and ultrasound at time of booking.;Criteria of severity of preeclampsia. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: Monitor for blood pressure and proteinuria and symptoms and signs.

—

Secondary

Measure	Time frame
Maternal bleeding that need to transfusion. Timepoint: From delivery for 24 hours after. Method of measurement: Signe and symptoms-decreasing of Hb after delivery-nu.;Intrauterine growth restriction. Timepoint: 2??? ??? ?? ???? ??????-?? 4 ????-????? ??????. Method of measurement: When the fetal weight will below the 10th percentile for gestational in ultrasound and also when the neonatal birth weight will fill bellow the 10th percentile.;Preterm delivery. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: LMP and ultrasound at time of booking.;Still birth. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: With FHR monitoring and ultrasound.	—

Measure

Time frame

Maternal bleeding that need to transfusion. Timepoint: From delivery for 24 hours after. Method of measurement: Signe and symptoms-decreasing of Hb after delivery-nu.;Intrauterine growth restriction. Timepoint: 2??? ??? ?? ???? ??????-?? 4 ????-????? ??????. Method of measurement: When the fetal weight will below the 10th percentile for gestational in ultrasound and also when the neonatal birth weight will fill bellow the 10th percentile.;Preterm delivery. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: LMP and ultrasound at time of booking.;Still birth. Timepoint: 2 month after onset-every 4 week-End of treatment. Method of measurement: With FHR monitoring and ultrasound.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Zoleikha Atarod

Mazandaran University of Medical Sciences

zatarod@mazums.ac.ir+98 15 1226 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026